Clovis Oncology traded at $2.85 this Friday July 1st, increasing $1.05 or 58.33 percent since the previous trading session. Looking back, over the last four weeks, Clovis Oncology gained 333.06 percent. Over the last 12 months, its price fell by 49.91 percent. Looking ahead, we forecast Clovis Oncology to be priced at 2.77 by the end of this quarter and at 2.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.85
Daily Change
58.33%
Yearly
-49.91%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 153.80 0.64 0.42% 33.54%
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
Acorda Therapeutics 0.48 0.01 3.20% -89.34%
Agenus 1.96 0.02 1.03% -64.49%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Anika Therapeutics 22.51 0.19 0.85% -49.04%
Arrowhead Research 35.96 0.75 2.13% -43.04%
AstraZeneca 10,808.00 54.00 0.50% 24.54%
Astrazeneca 65.95 -0.12 -0.18% 8.49%
Clovis Oncology 2.85 1.05 58.33% -49.91%
Enanta Pharmaceuticals 49.63 2.36 4.99% 12.29%
Esperion Therapeutics 6.45 0.09 1.42% -68.52%
GlaxoSmithKline 1,802.60 17.00 0.95% 25.84%
Halozyme Therapeutics 44.48 0.48 1.09% -4.18%
Heron Therapeutics 2.72 -0.07 -2.51% -81.71%
Incyte Corp 77.67 1.70 2.24% -7.07%
Insmed 20.89 1.17 5.93% -26.70%
Ligand Pharmaceuticals 90.58 1.36 1.52% -32.02%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Novartis 81.65 1.32 1.64% -3.02%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
Pfizer 52.31 -0.12 -0.23% 31.66%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Rigel Pharmaceuticals 1.25 0.12 10.62% -71.66%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sangamo BioSciences 4.28 0.14 3.38% -63.45%
Veracyte 21.10 1.20 6.03% -46.58%
Intrexon 1.41 0.07 5.22% -78.04%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and other international markets. The Company operates through two geographic segments: U.S. and ex-U.S. The Company’s product Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3). Its other product includes FAP-2286, which is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT).